Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

C-Path and Centogene Forge Alliance to Propel Drug Development for Lysosomal Diseases

NextEdge Admin

20 Jun 2024

1 min 48 sec

The Critical Path Institute (C-Path) and Centogene have entered into a memorandum of understanding (MOU) to establish a strategic partnership aimed at advancing drug development for rare lysosomal diseases. This collaboration will focus on several key areas, including enhancing data quality and integration for disorders such as Niemann-Pick disease type C, Gaucher disease types 2 and 3, and mucopolysaccharidosis type II. Centogene will contribute genetic testing services for clinical trials and observational studies, along with sample analysis reporting through its CentoCloud platform. Additionally, limited access to Centogene's Biodatabank will facilitate the analysis of patient data from the Critical Path for Lysosomal Diseases (CPLD) Consortium projects.

The MOU also outlines joint branding efforts to leverage the strengths of both organizations in addressing the challenges of lysosomal disease research and drug development. Krista Casazza, scientific director of the CPLD Consortium, highlighted the potential of this partnership to combine expertise and resources effectively.

Earlier in the year, Centogene partnered with the Michael J. Fox Foundation to explore genetic risk factors associated with Parkinson's disease, underscoring its commitment to advancing genetic insights across various diseases.